TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07182227: PS-002 for the Treatment of IgA Nephropathy in Adults

Sponsor: Purespring Therapeutics Limited · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 32 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,290,300

Rescue Site Savings

+$850,425

Unlock Full NCT07182227 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07182227 Rescue Dossier →